PAREXEL's Pharmaceutical R & D Statistical SourcebookPAREXEL International Corporation, 2002 - Drugs |
Contents
Pharmaceuticals | 1 |
RD Spending Abroad by Geographic Area Ethical Pharmaceuticals 19922000 | 7 |
Pharmaceutical Companies by RD Spending in 2000 and 2001 | 13 |
Copyright | |
46 other sections not shown
Other editions - View all
Common terms and phrases
active analysis annual applications Approval Phase Approval Time months AstraZeneca Aventis average Bayer biological Biopharmaceuticals biotechnology Bristol-Myers Squibb cancer Cardiovascular CBER CDER CenterWatch clinical development Clinical Phase clinical trials CMR International Cohort compounds cost CSDD drug delivery Drug Development drug discovery Drug Products drugs approved EMEA enrolled estimates FDA First Action FDA Second Action FDA Third firms gene Genentech genetic genomics Glaxo Wellcome GlaxoSmithKline Global growth increase IND filing Japan launch Lehman Brothers Lilly Mean Clinical Median Merck million NDA Approval NDA Review NMES Novartis Novo Nordisk orphan drug outsourcing percent Pfizer pharmaceutical companies pharmaceutical industry Pharmaceutical R&D Pharmacia pharmacogenomics Phase Phase Phase PhRMA pipeline Priority programs proteins R&D Expenditure R&D spending revenue Roche Schering-Plough Source Sponsor Response Study of Drug Success Rates Costs/Complexity survey targets technologies therapeutic areas Therapeutic Category therapy Total Approval Tufts Center Vaccines Worldwide